PPARA and Disorder of lipid metabolism: The lipid-lowering mechanisms of MSP2, MSP8, MSP10, MSP13 and MSP18 firstly demonstrated that they can ameliorate lipid metabolic disorders in vitro through regulating the AMPK pathway and its downstream protein factors on lipid synthesis (SREBP-1c) and degradation (PPAR-α and CPT-1).